|
|
| | CIMIFUGIN BETA-D-GLUCOPYRANOSIDE Basic information |
| Product Name: | CIMIFUGIN BETA-D-GLUCOPYRANOSIDE | | Synonyms: | CIMIFUGIN BETA-D-GLUCOPYRANOSIDE;5H-Furo[3,2-g][1]benzopyran-5-one,7-[(β-D-;glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-,(2S)-;Prim-O-glucosylcimifugin, 98%, from Cimicifuga foetida L.;(2S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-2,3-dihydrofuro[3,2-g]chromen-5-one;Cimifugin 7-glucoside;rim-O-glucosylcimifugin;5H-Furo[3,2-g][1]benzopyran-5-one, 7-[(β-D-glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-, (2S)- | | CAS: | 80681-45-4 | | MF: | C22H28O11 | | MW: | 468.45 | | EINECS: | | | Product Categories: | chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract | | Mol File: | 80681-45-4.mol |  |
| | CIMIFUGIN BETA-D-GLUCOPYRANOSIDE Chemical Properties |
| Melting point | 118~120℃ | | Boiling point | 736.9±60.0 °C(Predicted) | | density | 1.53±0.1 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMF: 15 mg/ml; DMSO: 15 mg/ml; Ethanol: 15 mg/ml; PBS (pH 7.2): 5 mg/ml | | form | powder to crystal | | pka | 12.94±0.70(Predicted) | | color | White to Light yellow | | Major Application | food and beverages | | InChIKey | XIUVHOSBSDYXRG-BZOGYWBENA-N | | SMILES | C12=C(C=C3O[C@H](C(C)(C)O)CC3=C1OC)OC(CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)=CC2=O |&1:5,19,21,24,26,28,r| |
| Safety Statements | 24/25 | | WGK Germany | WGK 3 | | HS Code | 29389090 | | Storage Class | 11 - Combustible Solids |
| | CIMIFUGIN BETA-D-GLUCOPYRANOSIDE Usage And Synthesis |
| Chemical Properties | White crystalline powder, soluble in methanol, derived from Fangji, Fangfeng, Huashan Qianhu. | | Uses | Prim-O-glucosylcimifugin have anti-inflammatory, immunosuppressive effects. | | Definition | ChEBI: PRIM-O-GLUCOSYLCIMIFUGIN is an organic heterotricyclic compound and an oxacycle. | | in vivo | Bronchoalveolar lavage fluid (BALF) is collected at 7 h after lipopolysaccharide (LPS) administration and the
cytokine levels in BALF are measured by ELISA. The levels of TNF-α, IL-1β and IL-6 in BALF are increased dramatically compared with control group. However, pretreatment with Prime-O-glucosylcimifugin (2.5, 5 or 10 mg/kg) significantly down-regulates the levels of TNF-α, IL-1β and IL-6 in a dose-dependent manner (P<0.05, P<0.01)[1]. | | target | | | IC 50 | iNOS; COX-2 |
| | CIMIFUGIN BETA-D-GLUCOPYRANOSIDE Preparation Products And Raw materials |
|